Concepedia

Author

Florence Namour

Galapagos (France)ORCID

Also Known As

F Namour, F. Namour, Florence Namour, Florence Namour (753693), Florence S. Namour

34

Publications

780

Citations

14

H-Index

17

Concepts

All Affiliations

Galapagos (France)Galapagos (Belgium)Gilead Sciences (United States)University of Bari Aldo Moro
FN

About

Florence Namour is an author at Galapagos (France) specializing in medicine, physiology, and applied physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

109

2

Health Sciences

2

2

82

3

Applied Physiology

2

2

82

4

Endocrinology

1

1

56

5

Exercise Physiology

1

1

26

Florence Namour

×

16

Publications

675

Citations

14

H-Index

YearCitations

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Florence Namour, Paul M. Diderichsen, Eugène Cox,

Clinical Pharmacokinetics

2015

134

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn,

Arthritis & Rheumatology

2017

75

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

Geert A. Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte,

Investigational New Drugs

2016

60

GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy

Anna Cozzoli, Roberta Francesca Capogrosso, Valeriana Sblendorio,

Pharmacological Research

2013

56

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions

Florence Namour, Julie Desrivot, Annegret Van der Aa,

Drug Metabolism Letters

2016

56

Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects

Florence Namour, René Galien, Tim Van Kaem,

British Journal of Clinical Pharmacology

2016

53

Identification of a 4-(Hydroxymethyl)diarylhydantoin as a Selective Androgen Receptor Modulator

F. Nique, Séverine Hebbe, Nicolas Triballeau,

Journal of Medicinal Chemistry

2012

51

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor

Florence Namour, Liesbeth Fagard, Annegret Van der Aa,

British Journal of Clinical Pharmacology

2018

31

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)

Jane C. Davies, Olivier Van de Steen, Silke van Koningsbruggen‐Rietschel,

Journal of Cystic Fibrosis

2019

27

Effects of Nandrolone in the Counteraction of Skeletal Muscle Atrophy in a Mouse Model of Muscle Disuse: Molecular Biology and Functional Evaluation

Giulia Maria Camerino, Jean‐François Desaphy, Michela De Bellis,

PLoS ONE

2015

26

Page 1